Flow cytometry: an interview with Clara Brando and Ted Baginski

Clara BrandoClara Brando

Dr Brando serves as a scientific and technical advisor for clients and internal teams for development, validation, and application of assays to ensure compliance with scientific and technical goals, and regulatory requirements. She leads client development programs with a focus on expanding the large molecule bioanalysis capabilities and customer base.

Dr Brando’s distinguished scientific career has held positions of increasing responsibility within the biopharmaceutical industry. After receiving her PhD in immunology from the University of Turin, Italy, Dr Brando held post-doctoral positions in cellular immunology, at the Laboratory of Immunology, National Institute of Allergy and Infectious Disease-NIH in Bethesda (MD, USA). Dr Brando served as a scientist at Temple University and the Wistar Institute in Philadelphia (PA, USA). where she investigated the mechanism of action of cytotoxic cells proposed as cell therapy for malignancies.

Ted BaginskiTheodore Baginski

Mr Baginski has over 25 years combined experience in the pharmaceutical and CRO industries. He has extensive experience in the design, qualification and validation of a wide variety of regulated and non-regulated immunoassays. His knowledge extends to technologies and methods related to RIA, Gyros, MSD, ELISA and flow cytometry platforms. His specialties include a unique ability to communicate and work with partnering groups on a technical level.


1 Could you introduce yourselves and explain your backgrounds in flow cytometry? [Time – 00:40]
2 What is you current research focused in and how to you apply this to flow cytometry? [Time – 02:52]
3 What challenges do you face when developing a flow cytometry assay? [Time – 05:23]
4 What technological improvements are required to improve flow cytometry? [Time – 08:38]
5 How can the field be regulated and standardized? [Time – 10:33]
6  How do you predict that flow cytometry will change in the next few years? [Time – 16:10]